These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

217 related items for PubMed ID: 21122554

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Hepatosplenic T-cell lymphoma in patients receiving TNF-α inhibitor therapy: expanding the groups at risk.
    Parakkal D, Sifuentes H, Semer R, Ehrenpreis ED.
    Eur J Gastroenterol Hepatol; 2011 Nov; 23(12):1150-6. PubMed ID: 21941193
    [Abstract] [Full Text] [Related]

  • 3. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease.
    Kotlyar DS, Osterman MT, Diamond RH, Porter D, Blonski WC, Wasik M, Sampat S, Mendizabal M, Lin MV, Lichtenstein GR.
    Clin Gastroenterol Hepatol; 2011 Jan; 9(1):36-41.e1. PubMed ID: 20888436
    [Abstract] [Full Text] [Related]

  • 4. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease.
    Mackey AC, Green L, Liang LC, Dinndorf P, Avigan M.
    J Pediatr Gastroenterol Nutr; 2007 Feb; 44(2):265-7. PubMed ID: 17255842
    [Abstract] [Full Text] [Related]

  • 5. Hepatosplenic T-cell lymphoma in a young man with Crohn's disease: case report and literature review.
    Ochenrider MG, Patterson DJ, Aboulafia DM.
    Clin Lymphoma Myeloma Leuk; 2010 Apr; 10(2):144-8. PubMed ID: 20371449
    [Abstract] [Full Text] [Related]

  • 6. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.
    Deepak P, Sifuentes H, Sherid M, Stobaugh D, Sadozai Y, Ehrenpreis ED.
    Am J Gastroenterol; 2013 Jan; 108(1):99-105. PubMed ID: 23032984
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Hepatosplenic T-cell lymphoma, immunosuppressive agents and biologicals: what are the risks?
    Subramaniam K, Yeung D, Grimpen F, Joseph J, Fay K, Buckland M, Talaulikar D, Elijah J, Clarke AC, Pavli P, Moore J.
    Intern Med J; 2014 Mar; 44(3):287-90. PubMed ID: 24621284
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Hepatosplenic T-cell lymphoma in a 47-year-old Crohn's disease patient on thiopurine monotherapy.
    van de Meeberg MM, Derikx LA, Sinnige HA, Nooijen P, Schipper DL, Nissen LH.
    World J Gastroenterol; 2016 Dec 21; 22(47):10465-10470. PubMed ID: 28058028
    [Abstract] [Full Text] [Related]

  • 11. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease: update.
    Mackey AC, Green L, Leptak C, Avigan M.
    J Pediatr Gastroenterol Nutr; 2009 Mar 21; 48(3):386-8. PubMed ID: 19274799
    [No Abstract] [Full Text] [Related]

  • 12. Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: a cautionary tale?
    Rosh JR, Gross T, Mamula P, Griffiths A, Hyams J.
    Inflamm Bowel Dis; 2007 Aug 21; 13(8):1024-30. PubMed ID: 17480018
    [Abstract] [Full Text] [Related]

  • 13. Use of case reports and the Adverse Event Reporting System in systematic reviews: overcoming barriers to assess the link between Crohn's disease medications and hepatosplenic T-cell lymphoma.
    Selvaraj SA, Chairez E, Wilson LM, Lazarev M, Bass EB, Hutfless S.
    Syst Rev; 2013 Jul 05; 2():53. PubMed ID: 23826928
    [Abstract] [Full Text] [Related]

  • 14. Hepatosplenic T-cell lymphomas and therapy with TNF-alpha-blocking biologics: a risk for psoriasis patients?
    Beyer M, Steinhoff M, Anagnostopoulos I, Assaf C, Sterry W.
    J Dtsch Dermatol Ges; 2009 Mar 05; 7(3):191-4. PubMed ID: 19192165
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Clinical features and treatment outcomes of 14 patients with hepatosplenic γ δ T-cell lymphoma.
    Wang Q, Jiang Y, Zhu Q, Duan Y, Chen X, Xu T, Jin Z, Li C, Wu D, Huang H.
    J Cancer Res Clin Oncol; 2021 Nov 05; 147(11):3441-3445. PubMed ID: 33856526
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Infliximab use and hepatosplenic T cell lymphoma: questions to be asked and lessons learned.
    Rosh JR, Oliva-Hemker M.
    J Pediatr Gastroenterol Nutr; 2007 Feb 05; 44(2):165-7. PubMed ID: 17255825
    [No Abstract] [Full Text] [Related]

  • 20. Hepatosplenic T-cell lymphoma following infliximab therapy for Crohn's disease.
    Drini M, Prichard PJ, Brown GJ, Macrae FA.
    Med J Aust; 2008 Oct 20; 189(8):464-5. PubMed ID: 18928444
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.